Literature DB >> 1919899

Reversible neurologic abnormalities associated with prolonged intravenous midazolam and fentanyl administration.

I Bergman1, M Steeves, G Burckart, A Thompson.   

Abstract

An encephalopathy developed in three infants in the intensive care unit after heavy sedation with midazolam and fentanyl for 4 to 11 days. The affected infants had poor social interaction, decreased visual attentiveness, dystonic postures, and choreoathetosis. Symptoms cleared completely in 5 days to 4 weeks. Retrospective review of records of all children treated in the intensive care unit with prolonged intravenous administration of midazolam revealed that 45 children could be assessed neurologically on withdrawal of sedation. Three children had definite and two had possible neurologic sequelae (5/45, 11.1%). All had received concomitant intravenous fentanyl therapy. Neurologic sequelae were significantly associated with young age, female gender, low serum albumin concentration, and concomitant administration of aminophylline. This encephalopathy may represent a benzodiazepine withdrawal syndrome, a prolonged agonist action on the benzodiazepine receptor, or the combined effects of multiple toxic, metabolic, and infectious insults to the central nervous system of infants in the intensive care unit. Prolonged use of intravenous midazolam sedation necessitates careful dosing, monitoring, and discontinuation, particularly in infants and young children.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1919899     DOI: 10.1016/s0022-3476(05)82420-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  18 in total

Review 1.  Intravenous midazolam infusion for sedation of infants in the neonatal intensive care unit.

Authors:  Eugene Ng; Anna Taddio; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2017-01-31

2.  Midazolam Responsive Oculogyric Crisis, Oral Automatisms, Akinesia and Rigidity Induced by Sedation Withdrawal in a Child.

Authors:  Robertino Dilena; Alberto Giannini; Alberto Cappellari; Sophie Guez; Alberto Priori
Journal:  Mov Disord Clin Pract       Date:  2014-06-06

Review 3.  Risk factors associated with iatrogenic opioid and benzodiazepine withdrawal in critically ill pediatric patients: a systematic review and conceptual model.

Authors:  Kaitlin M Best; Joseph I Boullata; Martha A Q Curley
Journal:  Pediatr Crit Care Med       Date:  2015-02       Impact factor: 3.624

Review 4.  Clinical pharmacokinetics of sedatives in neonates.

Authors:  E Jacqz-Aigrain; P Burtin
Journal:  Clin Pharmacokinet       Date:  1996-12       Impact factor: 6.447

5.  A reversible generalized movement disorder in critically ill children with cancer.

Authors:  Raja B Khan; Jeffrey E Schmidt; Robert F Tamburro
Journal:  Neurocrit Care       Date:  2005       Impact factor: 3.210

6.  Pediatric sedation: short-term effects.

Authors:  T L Slovis; C Parks; D Reneau; C J Becker; J Hersch; C D Carver; R D Ross; K Tech; R B Towbin
Journal:  Pediatr Radiol       Date:  1993

7.  Outpatient therapy of iatrogenic drug dependency following prolonged sedation in the pediatric intensive care unit.

Authors:  J D Tobias; J K Deshpande; D F Gregory
Journal:  Intensive Care Med       Date:  1994-08       Impact factor: 17.440

8.  Impact of a Standardized Treatment Guideline for Pediatric Iatrogenic Opioid Dependence: A Quality Improvement Initiative.

Authors:  Rima Abdouni; Teri Reyburn-Orne; Tarek H Youssef; Imad Y Haddad; Richard D Gerkin
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

Review 9.  [Neurotoxicity of general anesthetics in childhood: does anesthesia leave its mark on premature babies, newborns and infants?].

Authors:  B Sinner; K Becke; K Engelhard
Journal:  Anaesthesist       Date:  2013-02       Impact factor: 1.041

Review 10.  Clinical pharmacology of midazolam in infants and children.

Authors:  J L Blumer
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.